ArticleAnalytical and bioanalytical chemistry2021
Detection and evolution of SARS-CoV-2 coronavirus variants of concern with mass spectrometry.
Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Structural Phylogenetics with Protein Mass Spectrometry: A Proof-of-Concept.The protein journal · 2024Article
- Rapid identification of SARS CoV-2 omicron sub-variant JN.1 (BA.2.86.1.1) with mass spectrometry.Journal of mass spectrometry and advances in the clinical lab · 2024Article
- Multiplexed discrimination of SARS-CoV-2 variants via duplex-specific nuclease combined MALDI-TOF MS.Analytical and bioanalytical chemistry · 2024Article
- Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19.Advances in experimental medicine and biology · 2024Article
- Development of practical techniques for simultaneous detection and distinction of current and emerging SARS-CoV-2 variants.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023Review
- Discriminative Identification of SARS-CoV-2 Variants Based on Mass-Spectrometry Analysis.Biomedicines · 2023Article
- Development of a rapid and specific MALDI-TOF mass spectrometric assay for SARS-CoV-2 detection.Clinical proteomics · 2023Article
- Stability of ACE2 Peptide Mimetics and Their Implications on the Application for SARS-CoV2 Detection.Biosensors · 2023Article
- Advancement in COVID-19 detection using nanomaterial-based biosensors.Exploration (Beijing, China) · 2023Review
- Immunological and metabolic characteristics of the Omicron variants infection.Signal transduction and targeted therapy · 2023Article
- 25 Years Responding to Respiratory and Other Viruses with Mass Spectrometry.Mass spectrometry (Tokyo, Japan) · 2023Review
- Advances in virus detection methods for wastewater-based epidemiological applications.Case studies in chemical and environmental engineering · 2022Article
- Evaluation of Variant-Specific Peptides for Detection of SARS-CoV-2 Variants of Concern.Journal of proteome research · 2022Article
- Proteomic Analysis of Human Sputum for the Diagnosis of Lung Disorders: Where Are We Today?International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass mapping using high-resolution mass spectrometry has been applied to identify and rapidly distinguish SARS-CoV-2 coronavirus strains across five major variants of concern. Deletions or mutations within the surface spike protein across these variants, which originated in the UK, South Africa, Brazil and India (known as the alpha, beta, gamma and delta variants respectively), lead to associated mass differences in the mass maps. Peptides of unique mass have thus been determined that can be used to identify and distinguish the variants. The same mass map profiles are also utilized to construct phylogenetic trees, without the need for protein (or gene) sequences or their alignment, in order to chart and study viral evolution. The combined strategy offers advantages over conventional PCR-based gene-based approaches exploiting the ease with which protein mass maps can be generated and the speed and sensitivity of mass spectrometric analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.